IL-10-producing regulatory B cells induced by IL-33 (BregIL-33) effectively attenuate mucosal inflammatory responses in the gut by Sattler, Susanne et al.
s 
 
 
 
Sattler, S. et al. (2014) IL-10-producing regulatory B cells induced by IL-33 
(BregIL-33) effectively attenuate mucosal inflammatory responses in the 
gut. Journal of Autoimmunity, 50, pp. 107-122. 
 
 
Copyright © 2014 Crown Copyright 
This work is made available under the Creative Commons Attribution 3.0 
License (CC BY 3.0)  
 
 
 
 
Version: Published 
 
 
 
http://eprints.gla.ac.uk/105384 
 
 
 
Deposited on:  27 April 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
lable at ScienceDirect
Journal of Autoimmunity 50 (2014) 107e122Contents lists avaiJournal of Autoimmunity
journal homepage: www.elsevier .com/locate/ jaut immIL-10-producing regulatory B cells induced by IL-33 (BregIL-33)
effectively attenuate mucosal inﬂammatory responses in the gutq
Susanne Sattler a,1, Guang-Sheng Ling a,b,c,1, Damo Xu d, Leonie Hussaarts e,
Andreas Romaine a, Hongzhi Zhao a,f, Liliane Fossati-Jimack a, Talat Malik a,
H. Terence Cook a, Marina Botto a, Yu-Lung Lau c, Hermelijn H. Smits e, Foo Y. Liew d,
Fang-Ping Huang a,b,*
aDepartment of Medicine, Division of Immunology & Inﬂammation, Imperial College, London, UK
bDepartment of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
cDepartment of Paediatrics & Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
dDivision of Immunology, Infection and Inﬂammation, University of Glasgow, Glasgow, UK
eDepartment of Parasitology, Leiden University Medical Center, Leiden, The Netherlands
fDepartment of Hepatobiliary Surgery, Xinqiao Hospital, The Third Military Medical University, Chongqing, Chinaa r t i c l e i n f o
Article history:
Received 21 October 2013
Received in revised form
13 December 2013
Accepted 13 January 2014
Keywords:
IL-10
IL-33
Regulatory B cell
Mucosal inﬂammation
IBDAbbreviations: Breg, regulatory B cell; BregIL-33, IL
IBD, inﬂammatory bowel disease.
q This is an open access article under the CC BY lice
org/licenses/by/3.0/).
* Corresponding author. Department of Medicine
Inﬂammation, Imperial College, Hammersmith Hosp
W12 0NN, UK. Tel.: þ44 2033132397; fax: þ44 20331
E-mail address: fp.huang@imperial.ac.uk (F.-P. Hua
1 S.S. and G.S.L. contributed equally to the study.
0896-8411 Crown Copyright  2014 Published by Els
http://dx.doi.org/10.1016/j.jaut.2014.01.032a b s t r a c t
Regulatory B cells (Breg) have attracted increasing attention for their roles in maintaining peripheral
tolerance. Interleukin 33 (IL-33) is a recently identiﬁed IL-1 family member, which leads a double-life
with both pro- and anti-inﬂammatory properties. We report here that peritoneal injection of IL-33
exacerbated inﬂammatory bowel disease in IL-10-deﬁcient (IL-10/) mice, whereas IL-33-treated IL-
10-sufﬁcient (wild type) mice were protected from the disease induction. A phenotypically unconven-
tional subset(s) (CD19þCD25þCD1dhiIgMhiCD5-CD23-Tim-1-) of IL-10 producing Breg-like cells (BregIL-33)
was identiﬁed responsible for the protection. We demonstrated further that BregIL-33 isolated from these
mice could suppress immune effector cell expansion and functions and, upon adoptive transfer, effec-
tively blocked the development of spontaneous colitis in IL-10/mice. Our ﬁndings indicate an essential
protective role, hence therapeutic potential, of BregIL-33 against mucosal inﬂammatory disorders in
the gut.
Crown Copyright  2014 Published by Elsevier Ltd.Open access under CC BY license. 1. Introduction
B cells with immunosuppressive or regulatory capacity have
been described for many years [1e4], although the concept of Breg
as a distinct cell lineage of the immune regulatory network was not
formally introduced until more recently [5,6]. Various types of Breg
have since been shown including those of the B1 lineage (B1a/B10,
B1b) present in the peritoneal cavity [7e9], and the transitional-2 B-33-induced/expanded Breg;
nse (http://creativecommons.
, Division of Immunology &
ital, Du Cane Road, London
32379.
ng).
evier Ltd. Open access under CC BY liccells (T2-MZP, B2 lineage) found in the spleens of naïve mice
[10,11]. Similar to those of regulatory T cells (Treg), their regulatory
functions can be mediated by the release of immunosuppressive
cytokines or molecules [5,8,11,12]. There is also evidence suggesting
that Breg may serve as a tolerogenic antigen presenting cell (APC)
to induce Treg, or interact directly with pathogenic T effector cells
to inhibit their functions [5,13,14]. Importantly, there is now strong
evidence indicating their implications in different disease condi-
tions, including various autoimmune and inﬂammatory disorders
both in human and animal models [6]. However, the process and
factors involved in Breg induction, expansion and functions remain
obscure.
Interleukin-33 (IL-33) is a recently identiﬁed IL-1-like cytokine,
being the newest addition to the IL-1 super-family (IL-1F1e11)
[15,16]. IL-33, also termed IL-1F11, has been classiﬁed as an “innate
cytokine” associated with several inﬂammatory conditions,
particularly of the mucosal organs and tissues [15e22]. Human IL-
33 was initially detected in the airway epithelial cells, ﬁbroblasts
and smooth muscle cells constitutively, and after in vitroense. 
Fig. 1. Intra-peritoneal injection of IL-33 exacerbated enterocolitis in IL-10/ mice, but similarly treated WT control mice were protected from the IL-33-mediated mucosal
inﬂammation. Groups of IL-10/ and WT mice were injected i.p. with rhIL-33 (1 mg/mouse) twice a week, for 2 weeks starting at the age of 10 wk (A); or for 4 (B) or 6 (CeH) weeks
starting from the age of 7 wk. Clinical disease activities (diarrhoea, rectal prolapse) were monitored throughout and, at the end of experiments, pathological changes in the colon
and other organs or tissues assessed. AeB. Frequency of mice with signs of diarrhoea after IL-33 injection; CeF. Selected representative pictures showing colon enlargement (C),
colonic histo-pathological changes (disruption of mucosal architecture, ulceration, epithelial hyperplasia) (D), and heavy leukocyte inﬁltration including monocytes (CD11bþ) and
neutrophils (Gr1hi) (E), T (Thy1.2þ) and B (B220þ) cells (F) as well as IFN-g positive inﬁltrating T cells (G), in the colons of IL-33-injected IL-10/, but not WT control, mice. Data
shown in A and B are pooled from 3 repeated experiments and the group sizes are indicated in the graphs (A, B). For further quantitative analysis of the immunostaining results (Ee
G, histograms), an ImageJ (NIH) picture analysis software was used to calculate mean pixel ﬂuorescence intensity (see Methods). In order to control for background ﬂuorescence,
MFI was normalized for maximum pixel intensity. Quantitative and statistical analysis of the colonic leukocyte inﬁltrations was also carried out and shown (histograms) as part of E,
F and G respectively (n ¼ 5). H. Serum IFN-g levels of the mice. Statistical analysis: p values (AeB. Log rank test; EeH. Student’s t test).
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inﬂamed tissues from patients with ulcerative colitis and Crohn’s
disease, endothelial cells, intestinal epithelial cells and the colonic
sub-epithelial myoﬁbroblasts (SEMFs), constituted the major
source of IL-33 [17,20,23]. Abundant expression of endogenous IL-
33 was found in cells of the high endothelial venues (HEV) [17]
and within the inﬂamed mucosa [20,23]. In mice, IL-33 mRNA
and protein have also been detected in various organs and tissue
cells, including cells of the immune system such as macrophages
and dendritic cells (DC) [15,24]. ST2, an orphan receptor of the IL-1R
family cloned many years ago [25,26], and the very ﬁrst cell surface
lineage marker that we identiﬁed distinguishing Th2 from Th1
cells/clones [27], has recently been shown as a key component of
the IL-33 receptor (IL-33R) [15]. The functional IL-33R is a hetero-
dimer of ST2L (transmembrane form of ST2) and IL-1RAcP (IL-1R
accessory protein) [28], detected on various immune cell types
including Th2, B1 and mast cells [15,18,29e31].
IL-33 possesses multiple biological activities and may act in an
autocrine, paracrine or even intracrine (nuclear factor) manner
[15,17,32e34]. An interesting characteristic of IL-33 is that it belongs
to a special subset of cytokines, including IL-1a and HMGB1 (high-
mobility group box 1), which lead a “double-life” active both in theirsecreted and non-secreted (intracellular) forms, differentially
involved in the induction and modulation of inﬂammatory re-
sponses [15,17,34]. The unique feature of IL-33 is however about its
seemingly opposing pro-inﬂammatory versus anti-inﬂammatory
properties. In contrast to its IL-1a counterpart which drives pro-
inﬂammatory gene expression [35], the IL-33 intracellular precur-
sor protein has been found to act instead as a co-repressor of pro-
inﬂammatory genes, and its intra-nuclear binding could result in
an anti-inﬂammatory phenotype [17]. It has also been shown that
ST2 can dimerize with an alternative coreceptor of the IL-1R family,
SIGIRR (single Ig IL-1R related molecule), acting as a negative
regulator of the IL-33/ST2 signalling pathway [36].While its ligation
by IL-33 may result in the activation of MyD88, NFkB and MAPK
(mitogen-activated protein kinases) in Th2 andmast cells leading to
a preferential induction of Th2 cytokines (IL-5, IL-13), it may alter-
natively under certain condition also suppress IFN-g (Th1) produc-
tion via a hitherto unknown mechanism [15].
The immunological mechanism underlying such dichotomous
functions and complex regulatory properties of IL-33 remains
therefore to be understood. This may ﬁrst depend on its molecular
processing, release and the associated cellular compartments of the
cytokine. It is now believed that, similar to the chromatin-
Fig. 1. (continued).
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released by cells undergoing necrosis. As a result of cell damage, it
alerts the immune system of ‘danger’ (‘alarmins’) but otherwise
remains in the nucleus of living cells where it limits immune re-
sponses [37]. IL-33may also further exert its effects on different cell
types which in return regulate each other by releasing soluble
factors, as part of the immunological regulatory network or polar-
isation process [16].
We have recently demonstrated how necrotic cells or necrotic
cell-derived factors, and their complex interactions with dendritic
cells, could be directly involved in the induction of a lupus-likedisease in susceptible mouse strains [38,39]. Most importantly,
we showed that difference in susceptibility versus resistance to the
disease induction was critically depending on the presence or
absence of certain immune regulatory mechanism, and IL-10
appeared to be a crucial protective factor against the disease in-
duction. By using IL-10 gene-knockout (IL-10/) mice, we
demonstrated recently that, in the absence of IL-10 even the
resistant strain could be rendered susceptible to the induction of a
typical lupus-like renal disease [39].
These IL-10/ mice also develop spontaneously a Th1-
mediated chronic enterocolitis, and have been widely used as an
Fig. 2. High frequencies of CD25 expressing B cells (CD19þCD25þ) were detected in blood circulation of the IL-33-treated mice. Groups of IL-10/ and WT mice were injected i.p.
with rhIL-33 (1 mg/mouse) twice a week, for 6 weeks starting at the age of 7 wk. The mice were bled weekly and the peripheral blood mononuclear cells (PBMC) analysed by ﬂow
cytometry using ﬂuorescent conjugated antibodies speciﬁc for mouse CD19 and CD25. A. Selected representative FACS proﬁles of samples analysed at Week-2 after the 1st IL-33
injection. Kinetic changes in the frequency of CD19þCD25þ cells among total B cells (B) and of total lymphocyte population (C) were analysed. Data shown in B and C were pooled
from 2 repeated experiments (n ¼ 8e9). *p < 0.05; ***p < 0.001 (IL-33-treated WT versus IL-10/ groups, Student’s t test, 2 tailed).
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well-established that the pathogenesis represents an uncontrolled
Th1 response to normal gut ﬂora due to the lack of IL-10 that
normally down-regulates such a pathogenic T cell reactivity [43].
The present study was therefore designed to test and compare the
effects of IL-33, a Th2 type of cytokine whose release and expres-
sion have been associated with necrotic cell death, in -systemic
autoimmune and inﬂammatory disorders under the IL-10-deﬁcient
versus IL-10 sufﬁcient condition. We report here that peritoneal
injection of IL-33 accelerates IBD development in IL-10/mice, but
similarly treated WT mice were protected from the IL-33-mediated
mucosal inﬂammation. More importantly, we show further how a
closely associated and phenotypically unconventional subset or
subsets of IL-10-producing regulatory B cells (BregIL-33) induced by
IL-33 may counteract against the disease induction in WT mice.
These BregIL-33 cells, when isolated and adoptively transferred into
IL-10/mice, can also signiﬁcantly delay the onset of spontaneousIBD by restoring effectively immune homoeostasis in the IL-10
deﬁcient recipients.2. Results
2.1. IL-33 exacerbates enterocolitis in IL-10/ mice, whereas WT
mice are protected from the IL-33-mediated mucosal inﬂammation
To test and compare the effects of IL-33 in vivo under IL-10-
deﬁcient versus IL-10-sufﬁcient conditions, IL-10/ and WT
C57BL/6 mice were injected i.p. with IL-33. The mice were then
monitored for their general and clinical conditions related to IBD
development, including the onset and severity of diarrhoea, rectal
prolapse as well as bleeding. Blood samples were collected at reg-
ular intervals for phenotypic and functional analysis of leukocytes
in circulation, and for measuring serum cytokine levels.
Fig. 3. IL-33 induced a subset of IL-10 producing precursor B cells in the blood circulation of WT mice. Peripheral blood cells isolated from WT and IL-10/ mice at different time
points (as indicated in A, B and D; or at 2-weeks in C) after injection with different doses (as indicated, C) or a ﬁxed dose of recombinant hIL-33 (1 mg/mouse, AeB), mIL-33 (0.4 mg/
mouse, D), or with PBS only, by procedure described in Fig. 2 legend. The cells were cultured in the presence of PMA/Ionomycin and GolgiStop for 5 h s, and analysed for intracellular
IL-10 expression by FACS. A. Selected representative FACS proﬁles showing intracellular IL-10 expression in B cells (CD19þ) isolated from the hIL-33 treated WT C57BL/6 mice (top
panels), in comparisonwith those of similarly treated IL-10/ control mice (bottom panels). B. Kinetic changes in the frequency of IL-10 producing CD25þ B cells in blood circulation
following IL-33 injection. Data shown are mean values calculated from individual mice of each group (n ¼ 4) of one representative experiment. The experiments had been repeated
for more than 3 times with consistent results. C & D. Direct comparison of the in vivo effects, potencies and time kinetics of the human versus the mouse IL-33 on B cell activation
and IL-10 production. C. Dose-dependent changes in the frequency of CD25-expressing B cells appeared in blood circulation of WT mice following injection of hIL-33 or mIL33 of
different dosages as indicated. Data shown are means and standard errors calculated from 3 to 5 mice per group at 2-weeks after the ﬁrst IL-33 injection. D. Kinetic changes in the
frequency of IL-10 producing B cells in blood circulation following injection of hIL-33 (1 mg/inj.) or mIL-33 (0.4 mg/inj.). Values were derived from staining blood samples pooled in
equal volumes from 5 individual mice of each group (n ¼ 5), and the experiment has been repeated for at least 5 times with consistent results.
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but similarly treated WT C57BL/6 mice were essentially protected
from the IL-33-mediated mucosal inﬂammatory disease (Fig. 1).
The development of spontaneous colitis in IL-10/ mice is known
to be strongly inﬂuenced by environmental conditions. These micewere housed in the individual ventilated cages (IVC) as required by
the IC animal facility, and kept at SPF condition with sterilized food
and water. Therefore, few of them spontaneously developed diar-
rhoea before the age of 3 months. However, following IL-33 injec-
tion, we observed that the IL-10/ mice developed an early onset
Fig. 4. Phenotypic and functional characterization of the IL-33-induced Breg-like cells (BregIL-33) in the blood. AeC. Surface phenotype of BregIL-33: The IL-33-induced IL-10
producing B cells expressed high surface IgM (A), CD1d and CD25 (B), but down-regulated CD23 (FceRII) (B, C). Data shown in the table under (B) were results showing the
Mean MFI (SD) values calculated from results of 5 repeated experiments, as ratio of the IL-10B, and IL-10þB, cell subset over the total B cells gated. Statistical analysis: p values
(Student t test). DeF. In vitro Breg suppression assays: Immunosuppressive effects of the IL-33-induced Breg-like cells on B effector (Beff) cell proliferation (D), division (E), and its IL-
10 dependency (F). D. CD23þ B cells (Beff, 105) were cultured in the presence of anti-CD40 (2.5 mg/ml), with titrating (as indicated) doses of CD23 B cells (BregIL-33) puriﬁed from
the IL-33-injected mice. Cell proliferation was determined by thymidine incorporation at 48 h s. E. BregIL-33 (CD23-) puriﬁed from hIL-33-injected WT mice (Wk-2) were primed
with anti-CD40 (2.5 mg/ml) for 5 h before being added to CFSE-labelled CD23þ Beff cells. Cell division (CFSE dilution) was determined by ﬂow cytometry at day 5 of culture in the
presence or absence of LPS (0.5 mg/ml) or anti-IgM (5 mg/ml). F. IL-10 levels in the culture supernatants were quantiﬁed by ELISA (BD Biosciences).
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periments inwhich themicewere injectedwith IL-33, twice aweek
for two weeks starting at the age of 10-wk (A) or 7-wk (BeH)
respectively. One week after IL-33 injection, some of these mice as
young as 8-wks of age (Fig. 1B) started developing diarrhoea, and
80% of them had diarrhoea at the age of 11e12 weeks (Fig. 1A, B).
These mice also showed signs of severe rectal prolapse observableat much younger age and some evenwith bleeding, as compared to
the age-sex-matched PBS-treated control groups.
We had then performed detailed assessments on colonic tissues
taken from the mice after different treatment schemes mentioned
above (detailed in Fig. 1 legend) with various pathological changes
observed. The histo- and immune-pathological data shown in
Fig. 1CeH were selected from one of the experiments, in which the
Fig. 4. (continued).
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weeks. Fig. 1C shows representative pictures of colons collected at
the end of experiments from each of the IL-33 or PBS-injected IL-
10/ and WT mouse groups. The IL-33-treated IL-10/, but not
WT, mice had enlarged colons (Fig. 1C, Suppl. Fig. 1A). Subsequent
histological examination of the distal colon revealed typical path-
ological changes of IBD, featuring severe disruption of mucosal
architecture, ulceration and prominent epithelial hyperplasia, in
the IL-33-treated IL-10/ mice (Fig. 1D). Immunostaining of the
tissue sections also revealed heavy leukocyte inﬁltrations,
including high frequencies of monocytes (CD11bþGr1low) and
neutrophils (Gr1hi) (Fig. 1E), as well as T (Thy1.2þ) and B (B220þ)lymphocytes (Fig. 1F), in the inﬂamed colons. In comparison, some
scattered but signiﬁcantly less inﬁltrating leukocytes were found in
the PBS-treated IL-10/ mice (Fig. 1EeF). Among those colonic
inﬁltrating leukocytes, there was a high frequency of IFN-g
expressing T lymphocytes readily detectable in the IL-33-treated IL-
10/mice (Fig. 1G), which also correlated with serum IFN-g levels
in the mice (Fig. 1H). These results indicate that, in the absence of
IL-10, IL-33 may instead enhance the pathological Th1 response.
In contrast, none of the IL-33 or PBS-treated WT control mice
showed any sign of diarrhoea, rectal prolapse or bleeding, or evi-
dence of colonic histopathological and inﬂammatory changes
(Fig. 1EeG, and data not shown). In spite of the lack of colonic
S. Sattler et al. / Journal of Autoimmunity 50 (2014) 107e122114inﬂammation in the WT groups (Fig. 1), however, splenomegaly
was clearly evident in both IL-10/ and WT mice after IL-33
treatment (Suppl. Fig. 1B). This suggested that an ongoing process
of immune regulation could have occurred in the WT mice in
response to IL-33.
2.2. IL-33 induces a subset of IL-10-producing B cells in WT C57BL/6
mice
We next investigated the immunological mechanisms under-
lying susceptibility versus resistance to the IL-33-mediated
mucosal inﬂammation and, its regulation. We ﬁrst analysed T
cells in blood, including not only those of effector or activated
phenotype but also Treg known to play an important role in in-
testinal homoeostasis [44]. To our surprise, no signiﬁcant change
in the frequency of CD25þ T or Foxp3þ T cells in the IL-33-treated
mice, particularly at the early phase (Suppl. Fig. 1D, and data not
shown). In contrast, however, high frequencies of CD25
expressing B cells (CD19þCD25þ) were consistently detected in
the blood of IL-33-injected mice of both strains, as early as one
week after IL-33 injection (Fig. 2). More interestingly, these
CD25þ B cells appeared even earlier, and with higher frequency
either among total B (Fig. 2B) or total lymphocyte (Fig. 2C) pop-
ulation, in the WT compared to IL-10/ mice following IL-33
injection. Among them, we have subsequently identiﬁed a sub-
set of IL-10-producing B cells, which appeared early and time-
dependently in the blood of IL-33-treated WT mice (Fig. 3AeC).
The induction of Breg-like cells was initially observed using hu-
man recombinant IL-33 (hIL-33) but subsequently also conﬁrmed
by using the murine IL-33 (mIL-33) when it became commercially
available. The data shown in Fig. 3C and D compare their in vivo
effects, in terms of relative potency and time kinetics, on the
Breg-induction. Similar subsets of CD25þ and CD25þIL-10þ B
cells, and some T cells at a later time point (wk-5), were also
detected in the spleen and mesenteric lymph nodes
(Suppl. Fig. 1C, and data not shown) though of much lower fre-
quencies due to the heterogeneity and expansion of other cell
types, of both myeloid and lymphoid lineages, in these organs.
These results suggest that IL-33 could have induced a subset of
IL-10-producing Breg-like cells (BregIL-33) in vivo, protecting the
WT mice from IL-33-mediated mucosal inﬂammation.
2.3. Phenotypic and functional characterization of the BregIL-33
We then performed detailed phenotypic and functional char-
acterization of these IL-33-induced Breg-like cells. As shown in
Fig. 4, the IL-33-induced IL-10 producers had an unconventional
phenotype (CD19þCD25þCD1dhiIgMhiCD5-CD23-Tim-1-). They
expressed high surface IgM and CD1d, but lack CD5 and Tim-1
expression (Fig. 4AeB). Moreover, different from their
CD19þCD25- counterparts which were all CD23hi, the CD19þCD25þ
population appeared to contain 2 subpopulations, one CD23þ and
the other CD23-/low (Fig. 4C). The IL-10-expressing B cells in
particular had a substantially down-regulated CD23 (FcεRII)
expression, being almost exclusively of CD23 negative cells (Fig. 4B,
C). Such a feature allowed us to enrich and separate them from
majority of the non-IL-10 producers for their functional charac-
terization in vitro and in vivo.
To study their functionality, CD23- B cells puriﬁed from IL-33-
injected mice (designated BregIL-33) were cultured with the
CD23þ B cell population (designated effector B, Beff) at different
ratios, and in the presence or absence of either LPS, anti-mouse
CD40 or IgM antibodies. Cell proliferation was determined by
thymidine incorporation. As shown in Fig. 4D, addition of the WT
BregIL-33 (CD23-) dose-dependently suppressed the proliferativeresponse of CD23þ cells (Beff) to anti-CD40 stimulation. The
percentage of inhibition reached 55% at the high Breg to Beff
ratio (1:2). In contrast, the CD23- B cells puriﬁed from IL-33-
treated IL-10/ mice failed to suppress the Beff response, indi-
cating an IL-10-dependent mechanism was involved. Instead,
addition of these IL-10/ CD23- cells even resulted in an in-
crease in the total thymidine uptake values in the co-cultures
(Fig. 4D, right panel).
We have also found that signalling through CD40 could
effectively enhance the immunosuppressive functions of
BregIL33. In brief, freshly isolated CD23- B cells from IL-33-
injected mice (BregIL33) were pre-primed with an anti-CD40
Ab for 5 h before adding to the CFSE-labelled CD23þ
responder cells. The effects on Beff division in response to LPS or
anti-IgM stimulation were then determined by a CFSE dilution
assay. As shown in Fig. 4E, the anti-CD40-primed WT BregIL-33
(CD23) cells effectively inhibited Beff (CD23þ) cell proliferation
and division induced by LPS and, to some extent, anti-IgM
stimulation. Similar suppressive activity though weaker was
also observed when CD23- B cells isolated from PBS-injected
control mice (BregPBS) were used (data not shown). Impor-
tantly, the suppressive effect was found to be well associated
with the levels of IL-10 detected in the culture supernatants
(Fig. 4F). The results above thus indicate that IL-33 induces a
phenotypically unconventional subset or subsets of Breg-like
cells, and their IL-10-dependent immunosuppressive capacity
ﬁrst conﬁrmed in vitro.2.4. In vivo therapeutic effects of BregIL-33 on spontaneous IBD in IL-
10/ mice
We next investigated the role of BregIL-33 in vivo. CD23- B cells
isolated from IL-33-treated WT mice were adoptively transferred
intravenously into IL-10/ mice for two times at the age of 11-wk
and 13-wk. As shown in Fig. 5, the BregIL-33-treated mice had
improved clinical condition with a clearly reduced disease activity,
compared to the PBS-treated control mice. There was a signiﬁcant
delay in the onset of IBD in the BregIL-33-treated group, as indicated
by the percentage of mice with diarrhoea (Fig. 5A). The therapeutic
effects were also conﬁrmed by histological examination of the co-
lons. As shown in Fig. 5B, in contrast to the PBS-treated control mice
which showed typical though variable pathological changes of co-
litis, including mucosal thickening, crypt elongation, inﬂammatory
cell inﬁltration as well as crypt abscesses, no or minimal such
changes were observed in all of the ﬁve BregIL-33-treated IL-10/
mice. Although no signiﬁcant change was found in terms of body
weight (Suppl. Fig. 3A), the effects of BregIL-33 treatment on
splenomegaly and lymphadenopathy were also observed
(Suppl. Fig. 3CeD, and explained below).
To assess further the IL-10-dependency of the BregIL-33 therapy,
we analysed the suppressive functions of CD23- B cells isolated
from IL-33-treated IL-10/ mice (designated IL-10/BregIL-33).
Mice which received WT BregIL-33 but not IL-10/BregIL-33 had a
signiﬁcant delay in the onset of clinical disease (Fig. 6A), and a
reduction in the severity (Fig. 6B), as compared to the PBS-treated
mice. As shown in Fig. 6C, heavy colonic inﬁltration of CD11bþ (pan-
myeloid), Gr1high (neutrophils), Thy1.2þ (T) and B220þ (B) cells
were evident in the PBS-treated, and the IL-10/BregIL-33-treated
groups. In a clear contrast, very few of these cells could be detected
in the WT BregIL-33-treated group. Interestingly, there was certain
reduction in the colonic leukocyte inﬁltration observable in the IL-
10/BregIL-33-treated mice too (Fig. 6C, right panels). This suggests
that certain IL-10-independent mechanism could also be involved
in the protection, although the difference in the effects on T cells
Fig. 5. In vivo therapeutic effects of BregIL-33 on spontaneous IBD in IL-10-deﬁcient mice. Aged IL-10/ mice showed signiﬁcantly reduced diarrhoea (A) and absence of the typical
colonic histopathological changes (B), following adoptive transfer of BregIL-33 (CD19þCD23) puriﬁed from blood samples of the hIL-33-injected WT mice (Wk-2). The mice (5 per
group) were injected i.v. with BregIL-33 (106 cells per mouse) or PBS only (control), for 2 times at the age of 11-wk and 13-wk (arrows). The treated mice were then monitored for the
development of diarrhoea (A), sacriﬁced at the age of 18-wk (7 weeks after the 1st BregIL-33 treatment), and the colons processed for histological and pathological examinations (B).
For quantitative analysis (B, histograms), the ImageJ picture analysis software was used to count cell numbers by setting a signal strength threshold to select only dark nuclei and
counting the number of selected particles (see Methods). The experiment has been repeated for two times with consistent results. Statistical analysis: p values (MHL Log rank test).
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on the quantitative assessment (Fig. 6C & G histograms).
The BregIL-33-mediated protection is not only evident in sup-
pressing local inﬂammation in the colon, but also has a limiting ef-
fect on systemic inﬂammatory responses. The IL-10/mice treated
with exogenous WT BregIL-33, and to a less extent IL-10/BregIL-33,
were clearly prevented from developing splenomegaly, a clinical
condition usually caused by the inﬂammatory responses concomi-
tant with IBD development. The WT BregIL-33-treated group in
particular had a signiﬁcantly reduced spleen size (weight), with a
lower spleen/body ratio, as compared to the control groups (Fig. 6D,
Suppl. Fig. 3C). Similar suppressive effectswere also observed on the
number of leukocytes, including neutrophils (Gr1high), monocytes(CD11bþGr1low), DC (CD11cþ), B (CD19þ) and T (Th1.2þ) cells
(Fig. 6EeF, Suppl. Fig. 3B). The neutrophils, in particular, appeared to
be strongly and early responsive to the BregIL-33-mediated sup-
pression in terms of their total cell number (Fig. 6E) and ratio (time
kinetics, Suppl. Fig. 3B). Among the lymphocytic populations, total B
and Tcell counts were also signiﬁcantly decreased in theWT BregIL-
33 treatedmice (Fig. 6E). A reduction in the frequency of CD4þCD25þ
(activated) Tcellswas evident in theWTBregIL-33-treated group, but
the ratio of CD4þFoxp3þ Treg cells remained unchanged (Fig. 6F).
Furthermore, the BregIL-33 treatment appears to have effectively
suppressed the pathogenic Th1 responses in the mice (Fig. 6GeH).
While IFN-g expression could be still readily detected among the
remaining colonic inﬁltrating Tcells in the IL-10/BregIL-33-treated
Fig. 6. An essential role of IL-10 in the immunological mechanisms underlying BregIL-33emediated protection against spontaneous IBD in the mouse model. As described in Fig. 5
legend, groups of IL-10/ mice (5 and 10 mice per group as indicated in the graph) but at 10-wk of age were injected i.v. twice (at 10-wk and 12-wk) with CD19þCD23 cells
(106 cells per mouse) puriﬁed from blood samples of the IL-33-treated WT (WT BregIL-33), or IL-10/ (IL-10/BregIL-33), mice. Control group was IL-10/ mice injected with PBS
only (PBS). The mice were monitored twice weekly for signs of diarrhoea/disease development: A. Percentage of mice with diarrhoea. B. Diarrhoea severity scores. At the end of the
experiment (7 weeks after the 1st injection, 17-wk of age), the mice were sacriﬁced and different organs or tissues (colon, spleen, lymph nodes) and blood samples collected and
processed for assessments: CeH. Immunosuppressive effects of WT BregIL-33 and IL-10/BregIL-33 treatment on colonic leukocyte inﬁltration (C), splenomegaly (D), frequencies of
different leukocytes in peripheral blood circulation (E, F) and colonic inﬁltrating IFN-g expressing T cells (G), and on serum IFN-g levels (H). For further quantitative analysis of the
immunostaining results (C & G, histograms), the ImageJ (NIH) picture analysis software was used to calculate mean pixel ﬂuorescence intensity (see Methods). In order to control for
background ﬂuorescence, MFI was normalised for maximum pixel intensity. The data shown in DeF and H are results pooled from 2 experiments and presented as individual mice
(dot plots) within each of the experimental groups. Statistical analysis: A. p value in bold: WT BregIL-33-treated group versus PBS-treated control group; p value in bracket: WT
BregIL-33-treated group versus IL-10/BregIL-33-treated group (Log rank test). B, DeF and H: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test, unpaired, one-resp. two-tailed).
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mice (Fig. 6G), indicating an IL-10-dependent Th1-limiting effect
in vivo. This also correlates well with serum IFN-g (Fig. 6H), and
though less so IL-17 (Suppl. Fig. 3E), levels in the mice. Taken
together, the above ﬁndings have provided a good immunological
basis for the BregIL-33-mediated protection against mucosal in-
ﬂammatory disorders in the gut.
3. Discussion
In this study, we present evidence that IL-33 can be involved
not only in the exacerbation but also regulation of mucosal
inﬂammation in the gut, depending critically on the absence orpresence of IL-10. We showed that IL-33, a ‘Th2’ type of cytokine,
contributed signiﬁcantly to IBD development in mice lacking IL-
10. Similarly treated IL-10 sufﬁcient mice were however pro-
tected from the IL-33-mediated mucosal inﬂammation, and the
protection was closely associated with the induction of a
phenotypically unconventional subset or subsets of IL-10-
producing B cells. We demonstrated further, both in vitro and
in vivo, how these BregIL-33 cells could be responsible in pro-
tecting the WT mice from disease induction. More importantly,
upon adoptive transfer into IL-10/ mice, the BregIL-33 could
also block the development of spontaneous IBD by restoring
effectively immune homoeostasis in the IL-10 deﬁcient
recipients.
Fig. 6. (continued).
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is known to be much affected by environmental factors including
infections. However, we showed that the disease activity could be
enhanced by the injection of IL-33 alone. The outcome reﬂects
therefore a combination of the spontaneous and the IL-33-induced
disease activity in terms of its disease kinetics, which were found to
be related not only to the age of mice but more importantly the
frequency and length of the IL-33 injections. Several recent studies
have shown that the IL-33-ST2 axis is directly involved in mucosal
inﬂammatory disorders in the gut, but some seemingly conﬂicting
ﬁndings have been reported [45e48]. By using two experimental
mouse models of chemical induced IBD, triggered either by dextran
sodium sulphate (DSS) or by 2,4,6-trinitrobenzene sulphonic acid
(TNBS), Sedhom and colleagues showed that injection of IL-33
could accelerate colitis, and the disease induction could be effec-
tively prevented by blocking the IL-33-ST2 axis either throughgenetic ablation of the ST2 gene or the use of neutralizing anti-
bodies [45]. In an earlier study, Imaeda and colleagues showed that
while peritoneal injection of IL-33 could accelerate the disease, the
treatment also prevented the depletion of goblet cells in the DSS-
induced colitis, possibly through inhibition of the Notch signal-
ling [46]. In another study by Grob et al., interestingly, the IL-33
treatment was found to exert contrasting effects in the DSS-
induced model under acute versus chronic colitis conditions.
While IL-33 injection in acute colitis led to certain aggravation of
inﬂammation, it showed extenuating effects in chronic DSS-
induced colitis due to a shift of Th1 to Th2 responses [47]. Most
recent ﬁndings suggest that IL-4 could play a major role in the IL-
33-ST2 mediated acute inﬂammation in the gut [48].
Most intriguingly, our results show that IL-33, although branded
as a ‘Th2’ cytokine, appears to drive an enhanced Th1 type of
response under the IL-10-deﬁcient condition. This is evident by the
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inﬁltrating leukocytes including IFN-gþ T cells in the IL-33-injected
IL-10-deﬁcient but not WT control mice. This is also particularly
interesting, as Th1 responses have long been known to be crucially
involved being causative in IBD pathogenesis [49]. One possible
explanation could be that IL-10 might regulate Th1 response by
altering IL-33R expression. However, we found that there were
comparable levels of IL-33R (ST2L) on the cells, including various B
cell subsets, isolated from the IL-10-deﬁcient and WT control mice
(data not shown). Another possible explanation is that IL-33, as an
innate cytokine released by necrotic cells, could be involved in
orchestrating inﬂammation, favouring a Th1 response at an early
phase of immune reaction. As a result of negative feedback regu-
lation, i.e. due to overt inﬂammation at the later phase however,
excessive IL-33 release and ligation may down-regulate the Th1
response possibly through an IL-10-dependent mechanism. It
might do so for example by upregulating the negative regulator of
IL-33/ST2 signalling (SIGIRR), and thereby shifting the response
towards a Th2 phenotype [36,50]. In the absence of IL-10, however,
a failure in maintaining such a homoeostasis would allow perpet-
uation of the pathogenic Th1-mediated pro-inﬂammatory re-
sponses, responsible for the uncontrolled activation, expansion and
colonic inﬁltration of the pro-inﬂammatory leukocytes (neutro-
phils in particular) leading to IBD development.
Regulatory T cells have been shown to play an important role in
maintaining intestinal homoeostasis and the lack of Treg-mediated
suppression has been associated with IBD development [51]. A
recent study by Duan et al. suggests that IL-33 treatment could
protect against the TNBS-induced colitis by enhancing Foxp3
expression associated with Treg functions [52]. In the present
study, however, we observed little change in the frequency of either
Foxp3þ Treg or IL-10-producing CD4þ Tcells in the blood during the
early phase of IL-33 treatment. Although there was a modest effect
of IL-33 on Tcell expansion in the spleen at a relatively late stage, no
preferential Treg expansion was observed. In contrast, B cells
appeared to respond early and vigorously to IL-33with upregulated
CD25 expression. Among them, a discrete subset of IL-10-producing
Breg-like cells has been identiﬁed, counteracting against the IL-33-
mediated pro-inﬂammatory responses, potentially responsible for
the protection.
These BregIL-33 cells appear to have an unconventional pheno-
type (CD19þCD25þCD1dhiIgMhiCD5CD23Tim-1), and do not
appear to fall into either of the conventional B1 (CD5þ) or B2
(CD23þ) lineage. They share some phenotypic features with various
Breg subsets previously described, but differ in the expression of
other surface markers, including those of the B1a or B10 (CD5þ) [8],
B2 (CD23þ) [53] and B-Tim-1 (CD5þTim-1þ) [54] IL-10-producing B
cells. Though different still in terms of their heterogeneity in CD11b
expression (CD11bþ and CD11b subsets, data not shown), they
were more akin to the B1b sub-lineage
(CD1dhiIgMþCD5CD11bþCD23), an innate-like B cell subset pre-
viously shown to be induced under chronic inﬂammatory envi-
ronment associated with high IL-1 activity [9].
Importantly, we demonstrate here that these BregIL-33 cells,
when isolated and adoptively transferred into IL-10/ mice, can
block the development of spontaneous colitis in the IL-10-deﬁcient
recipients. The BregIL-33 treatment dramatically decreased the fre-
quency of IFN-g-expressing T cells in the colon, with signiﬁcantly
reduced serum IFN-g levels. However, there was again little change
in Treg frequency in the BregIL-33-treated mice, indicating the
therapeutic effects of BregIL-33 were likely through mechanisms
other than induction or expansion of Treg. The BregIL-33 cells may
do so by suppressing directly immune effector cells, including the
IFN-g producers. We present clear evidence here that these BregIL-
33 cells, by releasing IL-10, can also suppress the expansion ofvarious inﬂammatory innate immune cells, again neutrophils in
particular, both in the colon and in circulation of the IL-10 deﬁcient
mice. In future studies, it would also be interesting to test the
effectiveness of these Breg cells in protecting against directly the IL-
33-induced/accelerated disease, in addition to the age-dependent
spontaneous IBD development shown in the present study.
Taken together, our ﬁndings indicate that the IL-10-producing
BregIL-33 play an essential protective role against mucosal inﬂam-
mation. They may do so possibly by controlling the early phase of
inﬂammatory responses, similar to the so-called innate lymphoid
cells (ILCs) with regulatory functions recently described [55]. While
such regulatory mechanism appeared to be succeeded in the WT
strain, it failed badly in themice lacking IL-10. The lack of IL-10may
thus not only block Treg functions as previously documented, but
also prevent the induction and functions of the Breg-like cells in
response to IL-33 and possibly other inﬂammatory mediators.
These may together time-wise contribute to the break-down of
immunological homeostasis in the mice, leading to or being sus-
ceptible to the induction of various autoimmune and inﬂammatory
disorders. The present ﬁndings have therefore provided an
immunological basis for the BregIL-33-mediated protection, which
not only offers a good explanation for the dichotomous functions of
IL-33, but also points to the potential therapeutic value of BregIL-33
for treating mucosal inﬂammatory diseases in the future.
4. Materials and methods
4.1. IL-33 reagents
The recombinant human IL-33 (hIL-33), provided by our col-
laborators in Glasgow with a purity of more than 95%, had been
routinely tested for its endotoxin (LPS) levels (<0.01 EU/mg) by the
Limulus amebocyte lysate QCL-1000 pyrogen test (BioWhittaker).
Moreover, the bioactivity and speciﬁcity of our recombinant hIL-33
were also further conﬁrmed by its ability to induce IL-5 production
using Th2 cells polarized from WT and IL-33 receptor (IL-33R)
knock-out (ST2/) mice (ref.30). The recombinant mouse IL-33
(mIL-33) was obtained commercially with a purity of more than
98%, and an endotoxin level less than 1.0 EU/mg, according to the
supplier (R&D Systems Inc., UK).
4.2. Mice
Mice of the IL-10-deﬁcient (IL-10/) strain (B6.129P2-Il-
10tm1Cgn/J, H-2b; Stock no. 002251) were purchased from the Jack-
son Laboratory (Bar Harbor, ME, USA), and the wild type (WT)
C57BL/6 strain (H-2b) from the Charles River Laboratories, UK. The
IL-10/ mice develop spontaneously a chronic enterocolitis, and
have been used widely as an animal model of inﬂammatory bowel
disease (IBD) [40]. The intestinal inﬂammatory process is charac-
terized by focal transmural inﬂammation, mucosal hyperplasia and
extensive inﬁltration with CD4þ and CD8þ T cells, macrophages,
IgAþ plasma cells and scattered neutrophils [42]. Clinical signs of
inﬂammation include diarrhoea, perianal ulceration, intestinal
bleeding and occasional rectal prolapse. The disease severity is
largely depending on the housing environment. Different from the
general enterocolitis observed in IL-10/ mice from conventional
conditions, mice kept under speciﬁc pathogen-free conditions
exhibit less severe and only local inﬂammation restricted to the
colon [41,42]. All mice used for the present study were maintained
in individual ventilated cages, and set up as breeding pairs in the
Speciﬁc Pathogen Free Animal Facilities of Imperial College London.
All experiments involving live animals were carried out strictly
according to the protocols under licenses (PIL70/6877) approved by
the UK Home Ofﬁce.
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Groups of IL-10/ and WT mice (female, 7e10 weeks of age)
were injected i.p. with recombinant human IL-33 (hIL-33, 1 mg/
mouse) or murine IL-33 (mIL-33, 0.4 mg/mouse) in PBS (100 ml), or
with PBS only, twice a week for up to 6 weeks. The dose of IL-33
chosen was based on initial experiments in which serial doses of
hIL-33 and mIL-33 were tested and compared for their potency in
disease, as well as CD25þ B and BregIL-33 induction (Fig. 3C, and data
not shown). Clinical disease activities (diarrhoea) and changes of
leukocytes in peripheral blood were monitored throughout and, at
the end of experiments, pathological changes in the colons,
mesenteric lymph nodes and spleen assessed (detailed below).
4.4. Cell phenotype analysis by ﬂow cytometry
Phenotypic analysis of cells isolated from peripheral blood,
spleen and lymph nodes of mice before and after IL-33, or BregIL-33,
injection was performed using different combinations of
ﬂuorescent-labelled antibodies speciﬁc for mouse leukocyte sur-
face and intracellular markers. These antibodies, including anti-
Thy1.2-PE, anti-CD1d-PE, anti-CD4-APC, anti-CD5-FITC, anti-
CD11b-PE, anti-CD11c-APC, anti-CD19-PercPCy5, anti-CD21-FITC,
anti-CD23-PE, anti-CD25-PE, anti-IgD-PE, anti-IgM-PE, anti-TIM-
FITC, anti-ST2L, anti-Gr1-FITC and anti-Foxp3-PE, were obtained
commercially from BD Pharmingen (UK), with the exception of
anti-Foxp3 Ab (eBioscience) and anti-ST2L (MD Biosciences). For
intracellular detection of Foxp3, the cells were ﬁrst stained with
appropriate surface markers above, followed by the cell ﬁxation
and permeabilization procedures (as described below same for
intracellular cytokine detection), before incubation with the anti-
Foxp3-PE antibody.
Based on their staining patterns, different cell populations and
subpopulations including T (Thy1.2þ), B (CD19þ), helper T
(Thy1.2þCD4þ), regulatory T (Thy1.2þCD4þFoxp3þ), B1a
(CD19þCD11bþCD5þCD1dhi), B1b (CD19þCD11bþCD5-CD1dhi), B2
(CD19þCD5-CD1dþCD23þIgMhi) and B10 (CD19þCD5þCD1dhiC-
D23-IgMhiIL-10þ) cells, neutrophils (Gr1high), monocytes
(CD11bþGr1low) and dendritic cells (CD11cþ) were deﬁned and
quantiﬁed. For the ﬂow cytometry data, gating was based on the
use of respective isotype control antibodies, and the analysis was
performed using FlowJo 7.6.4 (TreeStar Inc, Ashland, OR, USA).
4.5. Intracellular staining for IL-10 expression
IL-10 expression of the IL-33-induced Breg-like cells was
measured ex vivo by incubating whole blood cells diluted 1:15 in
RPMI1640 cell culture medium, or puriﬁed mononuclear cells
(5  106 cells/ml), and stimulating them with PMA (50 ng/ml)/
Ionomycin (500 ng/ml) for 5 h at 37 C (5% CO2) in the presence of
GolgiStop (Becton Dickinson, UK). The cells were then labelled with
different cell surface markers mentioned above, before being ﬁxed
and permeabilized in the BD Cytoﬁx/Cytoperm buffer (Becton
Dickinson, UK), followed by immunostaining with anti-IL-10 anti-
body (BD Pharmingen). Contaminated red blood cells were then
lysed, white blood cells washed and re-suspended in FACS buffer
(BD Biosciences) before being loaded onto FACSCalibur for analysis
as described above.
4.6. BregIL-33 isolation
Based on their phenotypic characteristics, BregIL-33 cells were
enriched and isolated from peripheral blood of IL-33-injected WT
and IL-10/ mice for further functional characterization both
in vitro and in vivo. Brieﬂy, the mice were sacriﬁced at the peak ofBregIL-33 appearing in the blood, i.e. week-2 after the 1st IL-33 in-
jection (a total of 5 injections) (Fig. 3). Bloodwas harvested by heart
puncture and diluted in PBS þ5% EDTA. PBMC were ﬁrst isolated by
density separation using Lympholyte-Mammal medium (Cedarlane
Laboratories Ltd, Canada). Total B cells (CD43-) were then nega-
tively selected using the MACS CD43 microbeads (Miltenyi Biotec,
Germany), followed by depletion of CD23þ cells using an anti-
CD23-PE antibody (Clone B3B4, Becton Dickinson, UK) and anti-PE
microbeads (Miltenyi Biotec, Germany). All procedures were per-
formed according to the manufacturers’ instructions. Purities ob-
tained were: total B cells (CD19þ) >95%; of which the negatively
selected population (CD23 B cells) were >80%, and the remaining
positively selected (CD23þ B cells) >90%. The ﬂow through ob-
tained after both depletion steps was enriched in CD23 B cells
with IL-10 producing capacity (w3 folds), majority of which were
also of CD25þ B cells (data not shown).
4.7. In vitro BregIL-33 suppression assays
The in vitro suppressive capacity of BregIL-33 on B responder cell
proliferation and division was determined by the 3H-thymidine
uptake and CFSE dilution assays. Respectively, ﬁxed numbers (105)
of B responder cells (CD19þCD23þ) were cultured, in the presence
or absence of anti-CD40 (2.5 mg/ml, Enzo Life Sciences, UK), anti-
IgM (5 mg/ml, Thermo Scientiﬁc, UK) or LPS (0.5 mg/ml, Sigmae
Aldrich, UK), with titrated doses of BregIL-33 (CD19þCD23) isolated
from IL-33-treatedWTor IL-10/mice as described above. In some
experiments, puriﬁed BregIL-33 were ﬁrst primed by the anti-CD40
antibody (2.5 mg/ml, 5 h) before adding them to the responder cells.
For the cell proliferation assay, 1 mCi/well [3H]thymidine (Amer-
sham, UK) was added for the last 16 h, and the thymidine incor-
poration determined using a scintillation counter (PerkinElmer,
MA, USA). For the CFSE dilution assay, responder cells were pre-
labelled with CFSE (Molecular Probes, NY, USA), before co-
culturing and stimulation, and cell division (CFSE dilution)
measured by ﬂow cytometry.
4.8. Cytokine quantiﬁcation by ELISA
Levels of cytokines including IL-10, IL-17, IFN-g present in the
mouse serum or culture supernatants were quantiﬁed by com-
mercial ELISA kits according to the manufacturer’s instructions
(eBiosciences, UK).
4.9. Protocol for the in vivo BregIL-33 adoptive transfer experiments
To conﬁrm their disease-limiting effects in vivo, BregIL-33 iso-
lated from the IL-33-injectedWT (WT BregIL-33) or IL-10/ (IL-10/
BregIL-33), mice were adoptively transferred by intravenous in-
jection into groups of IL-10/mice. The recipient mice were given
a total of 2 injections of BregIL-33 (106 cells/injection) or PBS (Con-
trol), 2 weeks apart, starting at the age of 10e11 weeks. The mice
were monitored at least twice weekly for their general clinical
conditions, and signs of diarrhoea, rectal prolapse and bleeding as
detailed below. Blood samples were taken weekly for leukocyte
phenotyping and serum cytokine levels.
4.10. Clinical and pathological assessments for IBD
(1) Diarrhoea monitoring
During the IL-33 and BregIL-33 treatment experiments, mice
were monitored and recorded for diarrhoea twice weekly (both
frequency and severity). Monitoring was performed in a blinded
fashion, carried out consistently during early mornings and scored
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(soft faeces, wet hair) (þ); and obvious diarrhoea with redness and
hair-loss in anal area (þþ), severe redness and swelling of anal area
with retractable rectal prolapsed (þþþ), or permanent rectal pro-
lapsed (þþþþ).
(2) Histology for colitis assessment
Mouse colons were dissected and snap-frozen in OCT (VWR, UK)
and stored at 80 C, or ﬁxed in Bouin’s ﬁxative for 4 h and
embedded in parafﬁn, for histological analysis. The tissues were cut
(5 mm thick), and cryosections ﬁxed in cold acetone for 5 min and
air-dried, then stained with haematoxylin for 1 min and examined
using light microscopy.
(3) Immunostaining of colon tissue sections
The mouse colon cryosections were ﬁxed in acetone and stained
with ﬂuorescence-labelled antibodies speciﬁc for cell surface
markers of B cells (anti-B220-FITC), T cells (anti-Thy1.2-PE),
myeloid cells (anti-CD11b-PE) and neutrophils (anti-Gr1-FITC), and
IFN-g (anti-IFN-g-FITC) (all obtained from Cambridge Biosciences,
UK). Cell nuclei were visualized using DAPI containing mounting
ﬂuid (Dako UK Ltd, UK), and the sections were analysed using an
Olympus BX4 ﬂuorescence microscope (Olympus, UK). For further
quantitative analysis of the colonic pathological changes, the
ImageJ (NIH) picture analysis software [56,57] was used to calculate
mean pixel ﬂuorescence intensity and to count cell numbers. In
order to control for background ﬂuorescence, MFI was normalized
for maximum pixel intensity. Cell numbers were calculated by
setting a signal strength threshold to select only dark nuclei and
counting the number of selected particles.
4.11. Statistical analysis
ManteleHaenszel log rank (MHL) test was used to analyse the
statistical signiﬁcance of differences between mouse groups (diar-
rhoea development), in the IL-33 and BregIL-33 treatment experi-
ments. Student’s t-test was used for pair-wise comparison between
experimental groups in terms of changes in leukocyte frequencies
and cytokine levels. p  0.05 (*), p  0.01 (**), p  0.001 (***).
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